Small-Molecule Drug Services
-
Manufactured by Creative Biolabsbased in CHINA
mall molecule drugs are chemically synthesized active organic compounds with a low molecular weight usually less than 900 daltons which can be made into tablets or capsules that are easily absorbed. As traditional form of medicine, small molecule drugs have always been an important part of drug ...
-
based in USA
Simple : CarbonAI searches over 1.9 billion compounds to create synthesizable drug candidates – based only on target sequence. Precise : CarbonAI accurately identifies the most active and safe compound with a multi-objective optimization ...
-
Manufactured by CD Formulationbased in USA
One-Stop Solution for Small Molecule Drug Formulation: Small molecule drugs are chemically synthesized small molecules of active substances. Small molecule components can be made into tablets or capsules that are easily absorbed ...
-
based in USA
One of the challenges in drug discovery and development is miniaturization. Miniaturization is key to automating small molecule discovery, facilitating higher throughput, increasing reliability and accuracy and reducing costs for screening large compound libraries. We have a solid track record in miniaturizing challenging assays to 384- and ...
-
based in USA
. Rapid turnaround of assay data on new small molecule structures will enable a higher number of data driven decisions about hit optimization per unit time thereby reducing the time to progress a project into the lead optimization ...
-
based in USA
Strateos offers a wide range of the shelf assays and supports custom development of biochemical, biophysical and cellular assays using both industry-standard and innovative technologies to support drug discovery projects from hit identification to lead optimization. We also have broad experience in a variety of target classes ranging from ...
-
based in USA
Miniaturization is key to facilitating higher throughput, increasing reliability and accuracy and reducing costs for screening large compound libraries. We have a solid track record in miniaturizing challenging assays to 384- and 1536-well formats for medium to Ultra-High-Throughput Screening (uHTS). Strateos’ smart labs collectively span over 14K sqft and are composed of automated ...
-
based in USA
Hit discovery or hit identification in drug development is driven by the need to identify small molecules with desirable activity in a compound screen against a target. Our state-of-the-art fully automated robotic platform is set-up to accelerate your drug discovery process starting with robust, targeted hit identification ...
-
based in USA
High throughput screening (HTS) in drug discovery is critical for drug discovery and is a widely used tool for querying small molecule chemical libraries to determine the structure-activity relationship (SAR) of molecules and helps drive the development of specific and potent bioactive ...
-
based in GERMANY
Crystalsfirst Unlocks Chemical Matter On Scale By Putting Structural Data First. We have developed technologies that overcome current limitations of small molecule drug discovery. The integration of our high-performance structural biology, compound libraries with computational chemistry capabilities identifies novel molecules and ...
-
by Solvias AGbased in SWITZERLAND
We provide rapid and comprehensive support for your early-phase drug development process, enabling you to establish 'critical mass' – in terms of personnel and know-how – in the chemical and analytical development of complex small-molecule ...
-
by Kumudabased in USA
Innovation. Not just iteration. Disease biology is complex. Innovative integrated approaches are needed to unlock promising disease treatments. Kumuda is a therapeutics company that accelerates and de-risks novel small molecule drug discovery and development by applying an integrated multi-dimensional ...
-
Manufactured by ACROBiosystemsbased in USA
Macromolecules play an integral role in therapeutic research and development, encompassing therapeutic drugs such as monoclonal antibodies, recombinant proteins, polypeptides, antibody-drug conjugates (ADCs), and bispecific antibodies. Unlike small molecule drugs that are less than 1kDa, macromolecules have a ...
-
Manufactured by HemoShear Therapeutics, Inc.based in USA
Using our powerful REVEAL-TxTM drug discovery platform, our scientists are identifying and validating promising approaches to develop novel treatments aiming to extend and improve the quality of life of patients with rare diseases. In our most advanced program, the company is conducting a phase 2 clinical trial of HST5040, an oral small ...
-
Manufactured by CD Formulationbased in USA
of the bioavailability of the drug and patient compliance. CD Formulation develops microsphere technology and microsphere preparation processes based on a thorough understanding of the physicochemical properties of the loaded drugs (small molecule compound classes, peptides, proteins, herbal fractions, etc.), and then enables ...
-
Manufactured by Synbio Technologies LLCbased in USA
In recent years, the proportion of biological drugs in the global pharmaceutical market has been close to 20%. The focus within the global pharmaceutical market has been gradually shifting from small molecule chemical drugs to biomacromolecules (biological drugs). It also appears that the trend is gradually ...
-
based in UNITED KINGDOM
Finding rare events: The Lightcast platform is designed to have a high throughput and will be ideally suited to finding one in 10,000 or one in 100,000 ...
-
Manufactured by Ozgene Pty Ltd.based in AUSTRALIA
Knock-in mice have an insertion in a specific locus in order to produce genetically modified mice for customised research purposes. Reporter genes, human genes, related genes from the same organism, or point mutations can be introduced into the protein-coding region of a gene to produce knock-in mice. The difference between the knock-in and knockout approach is that knock-in mouse models are ...
-
Manufactured by BIOVECTRAbased in CANADA
BIOVECTRA’s analytical services group supports GMP and CMC requirements from early development to validation of commercial processes and continuous process verification, all along the life cycle of your programs. Our capabilities include regulatory-driven, phase-appropriate testing for both small molecules APIs and biologic ...
-
by Patheon Inc.based in USA
-leading performance. Whether you need small quantities of API for initial development work or many kilograms for a late phase trial, you can reduce the risk and raise the bar on quality of small molecule development with a partner whose reputation is built on both quality and excellence in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you